Vivek Jain - Envista Holdings Independent Director
| NVST Stock | USD 22.29 0.04 0.18% |
Insider
Vivek Jain is Independent Director of Envista Holdings Corp since 2020.
| Age | 60 |
| Tenure | 4 years |
| Address | Building E, Brea, CA, United States, 92821-6208 |
| Phone | 714 817 7000 |
| Web | https://envistaco.com |
Vivek Jain Latest Insider Activity
Tracking and analyzing the buying and selling activities of Vivek Jain against Envista Holdings stock is an integral part of due diligence when investing in Envista Holdings. Vivek Jain insider activity provides valuable insight into whether Envista Holdings is net buyers or sellers over its current business cycle. Note, Envista Holdings insiders must abide by specific rules, including filing SEC forms every time they buy or sell Envista Holdings'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Vivek Jain over three weeks ago Disposition of 12000 shares by Vivek Jain of ICU Medical at 88.76 subject to Rule 16b-3 | ||
Vivek Jain over three months ago Acquisition by Vivek Jain of 19306 shares of ICU Medical subject to Rule 16b-3 |
Envista Holdings Management Efficiency
The company has return on total asset (ROA) of 0.0169 % which means that it generated a profit of $0.0169 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3631) %, meaning that it created substantial loss on money invested by shareholders. Envista Holdings' management efficiency ratios could be used to measure how well Envista Holdings manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.04 in 2024. Return On Capital Employed is likely to drop to 0.01 in 2024. At this time, Envista Holdings' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 7 B in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 1.3 B in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kevin Thornal | Hologic | 50 | |
| Karen May | Alcon AG | 61 | |
| Brian Bonnell | ICU Medical | 50 | |
| Teresa Madden | The Cooper Companies, | 65 | |
| Vinayak Doraiswamy | AtriCure | 52 | |
| AM AM | ResMed Inc | 80 | |
| Candace Matthews | AptarGroup | 61 | |
| Dieter Spaelti | Alcon AG | 59 | |
| Constance Bienfait | ResMed Inc | N/A | |
| Francis Tan | Haemonetics | N/A | |
| Kimberly Martin | Alcon AG | 49 | |
| Yury Goltsev | Akoya Biosciences | N/A | |
| Gerard III | The Cooper Companies, | 59 | |
| Rajwant Sodhi | ResMed Inc | 46 | |
| Olga Guyette | Haemonetics | N/A | |
| Ines Poschel | Alcon AG | 50 | |
| Rajkumar Narayanan | Alcon AG | 56 | |
| Angela CPA | AtriCure | 46 | |
| Josep Llorens | Haemonetics | 62 | |
| Michel Voigt | Merit Medical Systems | 51 | |
| Neil Peterson | Merit Medical Systems | 57 | |
Management Performance
| Return On Equity | -0.36 | ||||
| Return On Asset | 0.0169 |
Envista Holdings Corp Leadership Team
Elected by the shareholders, the Envista Holdings' board of directors comprises two types of representatives: Envista Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Envista. The board's role is to monitor Envista Holdings' management team and ensure that shareholders' interests are well served. Envista Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Envista Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scott Huennekens, Independent Chairman of the Board | ||
| Amir Aghdaei, President, Chief Executive Officer, Director | ||
| Stephen Keller, Vice Relations | ||
| Paul Keel, CEO Director | ||
| Vivek Jain, Independent Director | ||
| Mischa Reis, Senior Vice President - Strategy and Corporate Development | ||
| Andrew Chen, Chief Officer | ||
| Christine Tsingos, Independent Director | ||
| Barbara Hulit, Independent Director | ||
| Gayle Sheppard, Independent Director | ||
| JeanClaude Kyrillos, Senior Vice President and President of the KaVo Kerr Business | ||
| Kieran Gallahue, Independent Director | ||
| Faez Kaabi, Chief VP | ||
| Suraj Satpathy, Chief officer | ||
| Daniel Raskas, Director | ||
| Juan Arbona, Chief Officer | ||
| Patrik Eriksson, Senior Vice President, President of the Nobel Biocare business | ||
| Wendy Carruthers, Independent Director | ||
| Eric Hammes, Chief Officer | ||
| Filippo Impieri, Senior Markets | ||
| Mark JD, General VP | ||
| Curt Bludworth, Chief Human Resource Officer, Senior Vice President | ||
| Mark Nance, Senior Vice President General Counsel, Secretary | ||
| Claudia Ortiz, Senior Assurance | ||
| Paul Sumilas, Chief Officer | ||
| Howard Yu, Chief Financial Officer, Senior Vice President | ||
| Eric Conley, VP Orthodontics | ||
| Jeffrey Kappler, Senior Vice President, President of the Ormco business |
Envista Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Envista Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.36 | ||||
| Return On Asset | 0.0169 | ||||
| Profit Margin | (0.53) % | ||||
| Operating Margin | 0.04 % | ||||
| Current Valuation | 4.42 B | ||||
| Shares Outstanding | 172.1 M | ||||
| Shares Owned By Insiders | 0.79 % | ||||
| Shares Owned By Institutions | 99.21 % | ||||
| Number Of Shares Shorted | 11.52 M | ||||
| Price To Earning | 17.57 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Envista Stock Analysis
When running Envista Holdings' price analysis, check to measure Envista Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Envista Holdings is operating at the current time. Most of Envista Holdings' value examination focuses on studying past and present price action to predict the probability of Envista Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Envista Holdings' price. Additionally, you may evaluate how the addition of Envista Holdings to your portfolios can decrease your overall portfolio volatility.